Adipose-derived stem cells (ASCs) can alleviate acute kidney injury and promote kidney cell regeneration and repair. To investigate the role of ASCs in diabetic nephropathy (DN), Sprague-Dawley rats were made diabetic by intraperitoneal injection of streptozotocin (STZ) after uninephrectomy. After 12 weeks, proteinuria was well established. Five times of 5×106 human ASCs repeatedly injected through a tail vein at 4 weekly intervals. A reduction in proteinuria was not observed in diabetic rats until 24 weeks. However, urinary protein excretion was significantly suppressed at 28 weeks and persisted up to 32 weeks after STZ treatment. ASC treatment significantly attenuated glomerulus hypertrophy and tubular interstitial injury, and led to the downregulation of WT-1 and synaptopodin expression. CFSE labeled ASCs were injected into DN rats via the tail vein. Within 24 h after injection, the cells were detected in lung, spleen, and peritubular regions, but rarely in pancreas. Human Alu gene expression was detected in lung and spleen up to 4 weeks after ASCs injection. ASC treatment did not improve hyperglycemia or pancreatic damage. In vitro, recombinant human glial cell line–derived neurotrophic factor (GDNF) prevented podocyte injury by high glucose similarly to ASC-conditioned medium. After blocking GDNF in ASC-CM with neutralizing antibody, the therapeutic effect of ASC-CM was significantly decreased. ASCs cocultured with podocytes restored the downregulation of synaptopodin expression, which was weakened by GDNF-RNA interfering. These findings indicate that repeated intravenous ASC can reduce diabetic kidney damage in rats even at the progressive stage, and promote podocyte recovery via GDNF secretion.
YangW, LuJ, WengJ, JiaW, JiL, XiaoJ, ShanZ, LiuJ, TianHet al.2010. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med, 362:1090–1101.
3.
ShawJE, SicreeRA, ZimmetPZ. Global estimates of the prevalence of diabetes for 2010, 2030. 2010. Diabetes Res Clin Pract, 87:4–14.
4.
MolitchME, DeFronzoRA, FranzMJ, KeaneWF, MogensenCE, ParvingHH, SteffesMW. American Diabetes Association. 2004. Nephropathy in diabetes. Diabetes Care, 27:S79–S83.
5.
ReutensAT, AtkinsRC. 2011. Epidemiology of diabetic nephropathy. Contrib Nephrol, 170:1–7.
6.
EzquerME, EzquerFE, Arango-RodríguezML, CongetPA. 2012. MSC transplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy. Biol Res, 45:289–296.
7.
MizunoH, TobitaM, UysalAC. 2012. Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells, 30:804–810.
8.
LockeM, FeisstV, DunbarPR. 2011. Concise review: human adipose-derived stem cells: separating promise from clinical need. Stem Cells, 29:404–411.
ZukPA, ZhuM, MizunoH, HuangJ, FutrellJW, KatzAJ, BenhaimP, LorenzHP, HedrickMH. 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng, 7:211–228.
11.
WickhamMQ, EricksonGR, GimbleJM, VailTP, GuilakF. 2003. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin Orthop, 412:196–212.
TobitaM, OrbayH, MizunoH. 2011. Adipose-derived stem cells: current findings and future perspectives. Discov Med, 11:160–170.
14.
LockeM, WindsorJ, DunbarPR. 2009. Human adipose-derived stem cells: isolation, characterization and applications in surgery. Anz J Surg, 79:235–244.
15.
LeeRH, SeoMJ, RegerRL, SpeesJL, PulinAA, OlsonSD, ProckopDJ. 2006. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA, 103:17438–17443.
16.
EzquerFE, EzquerME, ParrauDB, CarpioD, YáñezAJ, CongetPA. 2008. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant, 14:631–640.
LiK, HanQ, YanX, LiaoL, ZhaoRC. 2010. Not a process of simple vicariousness, the differentiation of human adipose-derived mesenchymal stem cells to renal tubular epithelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev, 19:1267–1275.
20.
CaoY, SunZ, LiaoL, MengY, HanQ, ZhaoRC. 2005. Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun, 332:370–379.
21.
ShiD, LiaoL, ZhangB, LiuR, DouX, LiJ, ZhuX, YuL, ChenD, ZhaoRC. 2011. Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-κB signaling. Exp Hematol, 39:214–224.
22.
DengW, HanQ, LiaoL, YouS, DengH, ZhaoRC. 2005. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol, 24:458–463.
23.
SusztakK, RaffAC, SchifferM, BottingerEP. 2006. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes, 55:225–233.
24.
MankheyRW, BhattiF, MaricC. 2005. 17β-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol, 288:F399–F405.
25.
NinichukV, GrossO, SegererS. 2007. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int, 70:121–129.
26.
CaldasHC, FernandesIM, GerbiF, SouzaAC, BaptistaMA, RamalhoHJ, Kawasaki-OyamaRS, Goloni-BertolloEM, Pavarino-BertelliEC, BraileDM, Abbud-FilhoM. 2008. Effect of whole bone marrow cell infusion in the progression of experimental chronic renal failure. Transplant Proc, 40:853–855.
27.
ChoiS, ParkM, KimJ, HwangS, ParkS, LeeY. 2009. The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Stem Cells, Dev18:521–529.
28.
AlexandreCS, VolpiniRA, ShimizuMHet al.2009. Lineage-negative bone marrow cells protect against chronic renal failure. Stem Cells, 27:682–692.
29.
PinoCJ, HumesHD. 2010. Stem cell technology for the treatment of acute and chronic renal failure. Transl Res, 156:161–168.
Meirelles LdaS, FontesAM, CovasDT, CaplanAI. 2009. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev, 20:419–427.
32.
MiasC, LairezO, TroucheE, RoncalliJ, CaliseDet al.2009. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells, 27:2734–2743.
33.
YoonBS, MoonJH, JunEK, KimJ, MaengIet al.2010. Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells. Stem Cells Dev, 19:887–902.
34.
LeeSR, LeeSH, MoonJY, ParkJY, LeeD, LimSJ, JeongKH, ParkJK, LeeTW, IhmCG. 2010. Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren Fail, 32:840–848.
35.
ThomasMC. 2011. Pathogenesis and progression of proteinuria. Contrib Nephrol, 170:48–56.
36.
SakodaM, ItohH, IchiharaA. 2011. Podocytes as a target of prorenin in diabetes. Curr Diabetes Rev, 7:17–21.32
37.
WhiteKE. 2006. Research into the glomerular podocyte-is it relevant to diabetic nephropathy?Diabet Med, 23:715–719.
38.
DurvasulaRV, ShanklandSJ. 2006. Podocyte injury and targeting therapy: an update. Curr Opin Nephrol Hypertens, 15:1–7.
39.
Yanagida-AsanumaE, AsanumaK, KimK, DonnellyM, Young ChoiH, Hyung ChangJ, SuetsuguS, TominoY, TakenawaT, FaulC, MundelP. 2007. Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53: mena signaling complexes in kidney podocytes. Am J Pathol, 171:415–427.
40.
GrossML, DikowR, RitzE. 2005. Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy. Kidney Int, 94:S50–S53.
41.
SaleemMA. Biology of the human podocyte. 2003. Nephron Exp Nephrol, 95:e87–e92.
42.
Dalla VestraM, ArboitM, BruseghinM, FiorettoP, IhalmoP, WessmanM, KaunistoMA. 2008. Association analysis of podocyte slit diaphragm genes as candidates for diabetic nephropathy. Diabetologia, 51:86–90.
43.
SrichaiMB, KonieczkowskiM, PadiyarA, KonieczkowskiDJ, MukherjeeA, HaydenPS, KamatS, El-MeanawyMA, KhanSet al.2004. A WT1 coregulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem, 279:14398–14408.
44.
KawachiH, MiyauchiN, SuzukiK, HanGD, OrikasaM, ShimizuF. 2006. Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton), 11:274–281.
45.
AsanumaK, Yanagida-AsanumaE, FaulC, TominoY, KimK, MundelP. 2006. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol, 8:485–491.
46.
MeniniS, IacobiniC, OddiG, RicciC, SimonelliP, FalluccaS, GrattarolaM, PuglieseF, PesceC, PuglieseG. 2007. Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia, 50:2591–2599.
47.
MiyauchiM, ToyodaM, KobayashiK, AbeM, KobayashiT, KatoM, YamamotoN, KimuraM, UmezonoT, SuzukiD. 2009. Hypertrophy and loss of podocytes in diabetic nephropathy. Intern Med, 48:1615–1620.
48.
CostantiniF. 2010. GDNF/Ret signaling and renal branching morphogenesis: from mesenchymal signals to epithelial cell behaviors. Organogenesis, 6:252–262.
49.
CostantiniF, ShakyaR. 2006. GDNF/Ret signaling and the development of the kidney. Bioessays, 28:117–127.
50.
TsuiCC, ShanklandSJ, PierchalaBA. 2006. Glial cell line-derived neurotrophic factor and its receptor ret is a novel ligand-receptor complex critical for survival response during podocyte injury. J Am Soc Nephrol, 17:1543–1552.
51.
HuangZY, HongLQ, NaN, LuoY, MiaoB, ChenJ. 2012. Infusion of mesenchymal stem cells overexpressing GDNF ameliorates renal function in nephrotoxic serum nephritis. Cell Biochem Funct, 30:139–144.
52.
ShiH, PatschanD, DietzGP, BährM, PlotkinM, GoligorskyMS. 2008. Glial cell line-derived neurotrophic growth factor increases motility and survival of cultured mesenchymal stem cells and ameliorates acute kidney injury. Am J Physiol Renal Physiol, 294:F229–F235.
53.
RotaC, ImbertiB, PozzobonM, PiccoliM, De CoppiP, AtalaA, GagliardiniE, XinarisC, BenedettiVMet al.2012. Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev, 21:1911–1923.
54.
HoJH, TsengTC, MaWH, OngWK, ChenYF, ChenMH, LinMW, HongCY, LeeOK. 2012. Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and β-cell differentiation in streptozocin-induced diabetic mice. Cell Transplant, 21:997–1009.
